Please assess the completion status of the following clinical trial:

Trial Title: Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Subject inclusion criteria:~1. Age 18 years or over.~2. At least one eye diagnosed with glaucoma and receiving maximally tolerated medical therapy.~3. Visually significant cataract with visual acuity of less than or equal to 6/12.~4. Subject able and willing to cooperate with investigation plan.~5. Subject willing to sign informed consent form.~Subject exclusion criteria:~1. Known allergic reaction to collagen.~2. Subject is on Warfarin and discontinuation is not recommended.~3. Subject with normal tension glaucoma or aphakic glaucoma.~4. Subject with corneal disease.~5. Participation in an investigational study during the 30 days proceeding phacotrabeculectomy.~6. Ocular infection within 14 days prior to phacotrabeculectomy.~7. Pregnant or breast-feeding women.~8. Monocular subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OculusGen Collagen Matrix (Type: None): OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).